Background-Ticagrelor and prasugrel provide stronger platelet inhibition compared with clopidogrel. Direct pharmacodynamic comparison between them has not yet been reported in ST-segment-elevation myocardial infarction. Methods and Results-In a prospective, single-center, single-blind study, 55 out of 117 (47%) screened consecutive STsegment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention were randomized to either ticagrelor 180 mg loading followed by 90 mg bid, or prasugrel 60 mg loading followed by 10 mg od for 5 days. Platelet reactivity (PR) was assessed with the VerifyNow P2Y12 function assay and the Multiplate Analyzer at 0, 1, 2, 6, 24 hours, and 5 days postrandomization. The primary end point, PR with VerifyNow at hour 1, did not differ significantly between patients randomized to ticagrelor versus prasugrel (257.3 P2Y12 reaction unit [PRU], 95% CI 230.8-283.8 versus 231.3 PRU, 95% CI 205.3-257.4; P=0.2). PR did not differ at 2, 6, and 24 hours, although at day 5 it was lower with ticagrelor than prasugrel (25.6 PRU, 95% CI 12.3-38.9 versus 50.3 PRU, 95% CI 36.4-64.1; P=0.01) . At hour 2, high on-treatment PR rates (cutoff 208 PRU) were 46.2% and 34.6% for ticagrelor and prasugrel, respectively, decreased significantly thereafter, whereas did not differ significantly between the 2 agents at all the time points of the study.
T he superiority of both prasugrel and ticagrelor over clopidogrel in the prevention of ischemic events has been demonstrated in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38 and the PLATelet inhibition and patient Outcomes (PLATO) trial, respectively. 1, 2 Therefore, prasugrel or ticagrelor administration is suggested as soon as possible in patients with ST-elevation myocardial infarction (STEMI)/acute coronary syndrome (ACS) by the 2010 the European Society of Cardiology/the European Association for Cardio-Thoracic Surgery guidelines on myocardial revascularization, and the 2011 the American College of Cardiology Foundation/ American Heart Association/Society for Cardiovascular Angiography and Interventions Guideline for Percutaneous Coronary Intervention. 3, 4 In healthy subjects or patients with stable coronary artery disease, prasugrel administered as a 60 mg loading dose (LD) achieves a significant antiplatelet effect at 30 minutes when no effect is detectable with 600 mg LD of clopidogrel. [5] [6] [7] Similarly, a stronger than clopidogrel platelet inhibition has been reported in ACS patients assessed ≥1 hour after prasugrel LD, although a high on-treatment platelet reactivity (HTPR), defined as a vasodilator-stimulated phosphoprotein PR index >50%, was present in 57% of the prasugrel-treated patients. 8 On the contrary, ticagrelor administered as a 180 mg LD provides marked inhibition of platelet activity within 1 hour in stable coronary artery disease and in ACS patients, with almost all patients being below the predefined cutoff points of HTPR. [9] [10] [11] The early and strong platelet inhibition seems to be of paramount importance in patients with STEMI undergoing primary percutaneous coronary intervention (PCI). 12 However, in the setting of STEMI there are specific conditions and a prethrombotic milieu that may affect antiplatelet agents absorption, metabolism, and subsequent pharmacokinetics and pharmacodynamics. 12, 13 Although the abovementioned superior antiischemic action with no excess bleeding of prasugrel and ticagrelor over clopidogrel was apparent in the STEMI subgroups of the TRITON-TIMI 38 and PLATO trials, respectively, 14, 15 pharmacodynamic studies of these drugs in the early, peri-primary PCI hours of STEMI are scarce. 8, 10 In a preliminary report of STEMI patients receiving prehospital treatment with 60 mg of prasugrel LD, the majority of them (60%) exhibited HTPR at the moment of PCI. 16 A suboptimal degree of early platelet inhibition achieved after a 60 mg LD of prasugrel at least for the first 2 hours in STEMI patients undergoing primary PCI has been also described. The simultaneous administration of high dose bolus tirofiban was able to bridge these first hours of incomplete platelet inhibition provided by prasugrel. 17 In addition, we have recently reported that in STEMI patients pretreated with 600 mg of clopidogrel and exhibiting HTPR 2 hours later, prasugrel reload is associated with up to 40% incidence of HTPR 2 hours later. 18 To the best of our knowledge, there have been neither previous pharmacodynamic studies with ticagrelor exclusively in STEMI patients nor a direct comparison of ticagrelor with prasugrel in such patients. Theoretically, because ticagrelor does not require previous metabolic activation, it may provide a faster than prasugrel platelet inhibition. 19 In the present study, we aimed to directly compare the pharmacodynamic actions of ticagrelor and prasugrel in STEMI patients undergoing primary PCI, a setting in which rapid and strong platelet inhibition is highly desirable.
Methods
We performed a prospective, randomized, single-center, single-blind, investigator-initiated, parallel design study to compare platelet inhibition by ticagrelor or prasugrel. Consecutive STEMI patients undergoing primary PCI with stent implantation were considered for PR assessment as early as possible on admission to our University hospital. Patient's randomization followed by immediate administration of the study drug was performed in the catheterization laboratory, directly after angiography. Patients were excluded if they had a history of stroke/transient ischemic attack, bleeding diathesis, chronic oral anticoagulation treatment, previous antiplatelet treatment, contraindications to antiplatelet therapy, PCI or coronary artery bypass grafting <3 months, hemodynamic instability, platelet count <100 000/μL, hematocrit <30%, creatinine clearance <30 mL/min, severe hepatic dysfunction, use of strong CYP3A inhibitors or inducers, increased risk of bradycardia, severe chronic obstructive pulmonary disease, or periprocedural IIb/IIIa inhibitors administration. Patients were randomized (hour 0) in a 1:1 ratio using computerized random-number generation by an independent investigator to ticagrelor 180 mg LD followed by 90 mg bid maintenance dose starting 12±6 hours post-LD, until day 5 or prasugrel 60 mg LD followed by 10 mg daily maintenance dose starting 24 hours post-LD, until day 5. All patients received oral aspirin 325 mg and 70 U/kg of unfractionated heparin intravenously at first medical contact and additional heparin or bivalirudin at the time of PCI per operator's discretion. After PCI, all patients received aspirin 100 mg/d indefinitely. Physicians and operators who performed platelet function testing were blind to the actual drug used, whereas an independent physician monitored bleeding and adverse event data. A flow chart diagram of the study is shown in Figure 1 . 
WHAT IS KNOWN
• Ticagrelor and prasugrel inhibit platelet aggregation to a greater degree than clopidogrel, which becomes apparent approximately 1 hour post loading dose.
WHAT THE STUDY ADDS
• Both ticagrelor and prasugrel exhibit an initial delay in the onset of antiplatelet effects in ST-segment-elevation myocardial infarction. • Platelet reactivity does not differ among patients treated with either ticagrelor or prasugrel during the first 24 hours of ST-segment-elevation myocardial infarction. Platelet reactivity before randomization
Multiplate Analyzer-Arbitrary aggregation units/min n=23 692±349 n=20 747±378 0.6 BMI indicates body mass index; CABG, coronary artery bypass grafting; FHCAD, family history of coronary artery disease; LVEF, left ventricle ejection fraction; PCI, percutaneous coronary intervention; PPIs, proton pump inhibitors; and PRU, P2Y12 reaction units.
Data are expressed mean±SD, medians (first to third quartiles) or n (%).
Platelet Aggregation Studies
PR assessment was performed at randomization/LD-administration (hour 0) and at 1, 2, 6, 24 hours after randomization, and on day 5 thereafter. Peripheral venous blood samples were drawn with a loose tourniquet through a short venous catheter inserted into a forearm vein. The first 2 to 4 mL of blood was discarded to avoid spontaneous platelet activation and blood was collected in 3.2% citrate (1.8 mL draw plastic Vacuette tubes; Greiner, Monroe, NC). Platelet function testing was performed with the VerifyNow (Accumetrics Inc, San Diego, CA) point-of-care P2Y12 function assay as previously reported. 20 The results are reported in P2Y12 reaction unit (PRU), BASE, and % inhibition. The % inhibition is calculated as: ([BASE−PRU]/BASE)×100. A value ≥230 PRU was considered as an indication of HTPR based on a previous investigation, linking the cutoff point to post-PCI ischemic risk. 21 A post hoc analysis was also performed using the threshold of 208 PRU. 22 Additional platelet function analysis was performed using the Multiplate analyzer (Dynabyte Informationssysteme, Munich, Germany). Results are reported in arbitrary aggregation units-AU/min with a value ≥468 indicating HTPR. 23, 24 
End Points
The primary end point of the study was PR at hour 1 between the 2 treatment groups. Secondary end points involved PR at 2, 6, 24 hours, and day 5 and HTPR rates at 1, 2, 6, 24 hours, and day 5 between the 2 treatment groups. Documentation of major adverse cardiac events (death, myocardial infarction, stroke, and revascularization procedure with PCI or coronary artery bypass grafting) and serious adverse events (bleeding, other adverse events) was performed until day 5.
Statistical Analysis
Categorical data are presented as frequencies and group percentages. Continuous data with normal and skewed distribution are presented as mean±SD and medians (first to third quartiles), respectively. The Kolmogorov-Smirnov test was used to examine data distribution normality. Two-sample t test and Fisher exact test were used for comparison of normally distributed continuous and categorical data, respectively. The Mann-Whitney U-test was used for comparison of skewed continuous data. The primary end point as well as PR at all the other time points of the study were analyzed separately via a mixed effect model with treatment as fixed effect, patient as a random intercept, and PR at baseline as a covariate. No adjustment for multiple comparisons was made. Least squares estimates of the mean difference are presented, with 95% CI and a 2-sided P value for the treatment effect. The rate of onset (slope) of the antiplatelet effect curve from 0 to 2 hours was assessed by a mixed linear model with patient as a random intercept, treatment, time, and treatment by time interaction as fixed effects. Difference for the slopes and 95% CIs for the treatment effect are presented. All tests were 2-tailed and statistical significance was considered for P values <0.05. All statistical analyses were performed using SPSS for Windows (version 16.0 SPSS Inc, Chicago II).
Sample Size Calculation
At the time of study design, no data were available about the early pharmacodynamic response of ticagrelor and prasugrel in the clinical setting of STEMI. Based on previously published data involving patients with stable coronary artery disease 9, 25 , we hypothesized that ticagrelor 180 mg LD would be superior to prasugrel 60 mg LD with a PR absolute difference of 80 PRU at 1 hour postrandomization, with the assumption that the SD of PR within groups will be 65 PRU and that the covariate (baseline PR) has an R-squared of 0.2. Choosing a power of 90% and a 2-sided a-level of 0.05, at least 26 patients in total (13 in each group) would be required to reach statistical significance.
The study protocol was approved by the ethics committee and was conducted according to the principles of the Declaration of Helsinki. All patients provided written informed consent before enrollment.
Results
Out of 117 consecutive patients with STEMI, 55 (47%) were eligible for participation in this study and were randomized to either ticagrelor or prasugrel. There were no differences in demographic and clinical characteristics between the 2 groups ( Table 1 ). The primary end point, PR with VerifyNow at hour 1 after drug administration did not differ significantly in patients randomized to ticagrelor or prasugrel ( Table 2) . PR at 2, 6, and 24 hours did not differ significantly between ticagrelor-and prasugrel-treated patients. At day 5 postrandomization, PR was lower in the ticagrelor than in prasugrel-treated patients ( Table  2) . Individual values of PR with the VerifyNow at all the time points of the study are shown in Figure 2A . The rate of onset (slope) of the antiplatelet effect curve from hour 0 to hour 2 with the VerifyNow assay did not differ significantly between ticagrelor and prasugrel-treated patients: −23.9 PRU/h, intercept 249.2 versus −44.6 PRU/h, intercept 254.8, respectively, difference in slope 20.7 PRU/h, 95% CI −46.9 to 5.46, P=0.1.
The area under the curve from hour 0 to hour 6 (assessed with the linear trapezoidal method) was 1017.0 PRU×hour and 876.2 PRU×hour for ticagrelor and prasugrel, respectively.
Similar results were obtained with the Multiplate Analyzer, although the PR difference at day 5 was marginally nonsignificant (Table 3) . Individual values of PR at all the time points of the study with the Multiplate Analyzer are shown in Figure  2B Supplement Table I. The HTPR rates at the different time points of the study in ticagrelor-and prasugrel-treated patients according to the method and threshold used are shown in Figure 3 . At hour 1, HTPR rates ranged from 52.2% to 74.1% and 45% to 66.7% according to the method and threshold used for ticagrelor and prasugrel, respectively. At hour 2, HTPR rates ranged from 31.8% to 46.2% and 20% to 34.6% for ticagrelor and prasugrel, respectively. HTPR rates were effectively decreased by both agents thereafter, whereas did not differ significantly between the 2 agents in any of the time points of the study (Figure 3 , online-only Data Supplement Table II-IV) .
In total, 4 study patients died before completion of day 5. Οne patient was allocated to ticagrelor arm and died during day 5 from stroke. No autopsy was performed. The other 3 patients were allocated to prasugrel arm, 2 of them died on day 1 from pump failure and the other on day 4 during emergency operation for ruptured papillary muscle. No major bleedings occurred in either treatment arm, 4 patients (3 allocated to ticagrelor and 1 to prasugrel arm) experienced minor or minimal bleeding events.
Discussion
Our study represents the first characterization of ticagrelor antiplatelet effect profile in comparison with prasugrel in the setting of STEMI. After a delayed onset of action, from what would be predicted based on assessments in stable patients, ticagrelor appears not to be superior to prasugrel in reducing PR during the first 24 hours of STEMI. However, at day 5 ticagrelor provided a lower PR than prasugrel. The mechanisms and possible clinical impact of this initial delayed ticagrelor's and prasugrel's antiplatelet effect, and the late Prasugrel pharmacodynamics in STEMI patients have been recently reported with a suboptimal degree of early platelet inhibition achieved after a 60 mg LD of prasugrel in the first 2 hours or by the time primary PCI is performed. [16] [17] [18] Beyond 6 hours postprasugrel LD a satisfactory platelet inhibition was seen. 17 Our results in the prasugrel arm are in the same line of evidence. Of note, in an ACS population (42.5% with STEMI) receiving 60 mg of prasugrel, 25.2% exhibited high PR as assessed by Vasodilator-stimulated phosphoprotein index 6 to 12 hours postloading. 26 Because ticagrelor is an active drug itself and has a simpler metabolism leading to the formation of an also active metabolite (AR-C124910XX) via CYP3A4 enzymes, one would expect a faster than prasugrel onset of action. 19 This hypothesis was not confirmed in our STEMI population. In healthy volunteers, ticagrelor reaches its maximal plasma concentration in about 1.5 hour, after LD. 27 In stable coronary artery disease patients, a fast onset of action has been described with a significant antiplatelet effect apparent as early as 30 minutes after 180 mg ticagrelor LD and achieving near-maximal (>80%) platelet inhibiting response within 1 hour. 9 At this time point, nearly all patients treated with ticagrelor (97%) were below the predefined cutoff points of HTPR. 11 In the small-sized PLATO PLATELET substudy, ticagrelor achieved marked inhibition by 1 hour postdosing in 4/5 STEMI and in 7/7 non-STEMI patients reported. 10 In our STEMI population however, at 1 hour and 2 hour postticagrelor LD time points assessed, a significant proportion of patients still exhibited HTPR allowing us to speculate that primary PCI even with prehospital ticagrelor administration most likely is to be performed with PR levels above the threshold(s) associated with adverse events obtained from studies in non-STEMI patients. 24 A possible mechanism explaining the above might relate to impaired drug absorption in the setting of STEMI. Indeed, a disturbed clopidogrel absorption possibly leading to impairment in its pharmacokinetics and pharmacodynamics has been described in STEMI patients. 13 However, robust evidence regarding prasugrel or ticagrelor impaired absorption in STEMI patients is lacking as it needs pharmacokinetic confirmation. Of note, although ticagrelor is a putative P-glycoprotein substrate, the ABCB1 polymorphism had no effect in outcome of the ticagrelor-treated patients in the PLATO trial. 28 Another explanation of the above findings might lie in the highly thrombotic milieu of STEMI. An early high PR in STEMI has been described to predict the primary PCI angiographic success, the degree of ST-segment resolution, the extent of myocardial necrosis, and the short-and midterm clinical outcome in studies where clopidogrel had been used as an oral antiplatelet agent. [29] [30] [31] An inadequate platelet inhibition in the very first hour(s) in some STEMI patients has been proposed as possibly responsible for the lack of a significant antiischemic benefit of prasugrel compared with clopidogrel in primary PCI, in contrast to what observed in secondary PCI patients. 14 As suggested in the recently reported PLATO ST elevation ECG study, the absence of any ticagrelor advantage versus clopidogrel on the ST resolution observed at day 3 might be associated with a delayed or incomplete acute reperfusion by ticagrelor. 32 The above evidence implies that in a setting where early and strong platelet inhibition is of utmost importance, despite the recent developments in antiplatelet treatment, there is need for further improvement. Indeed, bridging of prasugrel initial delayed platelet inhibition with administration of tirofiban has been proposed. 17 Most importantly, our study shows for the first time that an initial delay of ticagrelor action also exists in STEMI and this may support the conduction of similar studies. Additionally, other intravenous agents like cangrelor could represent an alternative way for covering prasugrel's or ticagrelor's initial antiplatelet action gap. Alternatively, because in healthy volunteers the peak plasma concentration (Cmax) for ticagrelor is a function of the administered dose, 27, 33 a higher LD in patients with STEMI could theoretically achieve a faster platelet inhibition. Finally, another way of overcoming this delayed onset of antiplatelet drug action Beyond the first 24 hours of STEMI, PR achieved at day 5 with ticagrelor was lower compared with prasugrel. This is in agreement with the first direct pharmacodynamic comparison between ticagrelor and prasugrel recently reported by our group in patients with ACS and exhibiting high on-clopidogrel PR 24 hours post-PCI. 34 The clinical significance of the observed antiplatelet superiority of ticagrelor at day 5 is unknown, namely whether it translates to less ischemic and more bleeding episodes or has no measurable clinical effect at all.
Implications
Our study was a purely pharmacodynamic one comparing the antiplatelet effects of ticagrelor and prasugrel in the setting of primary PCI for STEMI. The temptative clinical comparison of ticagrelor versus prasugrel in STEMI patients should take into account the overall minor pharmacodynamic differences observed between the 2 agents. An important observation was that there is a delay in action of both agents during the first 2 hours postloading. Whether this is partly attributed to impaired absorption of the drugs in the setting of STEMI needs to be proved with pharmacokinetic studies. In addition, this observation raises the question whether a higher LD of both drugs, earlier administration or bridging with a rapidly acting intravenous antiplatelet agent, might be effective ways to overcome heightened PR during the first 2 hours of STEMI.
Study Limitations
Only 2 out of the several existing methods for platelet function have been used in our study. Because of the poor correlation between tests, the lack of agreement on the ideal and the most clinical relevant test or the threshold of response for each test, our results apply for the used methodology. 24 The size and the duration of our study did not allow us to assess any possible relation of platelet function results with patients' outcome. We did not aim to look at other nonantiplatelet or pleiotropic actions the 2 agents, particularly ticagrelor with its adenosine like action, may have. Our study failed to confirm the originally planned superiority hypothesis of ticagrelor over prasugrel. Because the within-groups SDs were wide relative to the treatment differences observed, a larger sample size would provide better precision and higher power. With the size of our study, a possible faster onset of action of prasugrel than ticagrelor cannot be excluded with certainty. However, the initially hypothesized difference, namely faster ticagrelor onset of action, is highly unlikely.
Conclusions
In patients with STEMI undergoing primary PCI, ticagrelor and prasugrel, after an initial delay in the onset of their antiplatelet action, do not differ during the first 24 hours. Thereafter, ticagrelor provides a stronger than prasugrel platelet inhibiting effect. Clinical comparison of the 2 antiplatelet agents in STEMI patients is eagerly expected.
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